Heraeus adds ‘much-needed’ capacity for chemo components manufacture

By Vassia Barba

- Last updated on GMT

(Image: Heraeus)
(Image: Heraeus)

Related tags Chemotherapy High potency apis High potency Active pharmaceutical ingredients Active pharmaceutical ingredient API

Heraeus adds production line to expand its capacity for the manufacture of platinum-based HPAPIs.

Germany-headquartered Heraeus Pharmaceutical Ingredients announced an expansion of its manufacturing capacity for platinum-based highly potent active pharmaceutical ingredients (Pt HPAPIs), which are a key component in cancer chemotherapies.

More specifically, Pt HPAPIs are used in treatments against a range of cancers, including lung, colorectal, ovarian and testicular.

The company suggested that this expansion comes “as cancer cases rise across the globe,” ​and in order to ensure the company possesses “much-needed capacity to meet the long-term global market demand.”

Moreover, Heraeus stated that the need for Pt HPAPIs in cancer treatment has been ‘rocketing’ due to demographic changes leading to more cancer cases, emerging countries gaining access to chemotherapy and usage of the components in combination therapies.

The production line will be established at the company’s facilities in Hanau, Germany, with commercial production scheduled to begin in 2020, upon completion of regulatory certification.

Marcus Hannakam, head of Heraeus’ Pharmaceutical Ingredients Business Line, stated that this forms a ‘multi-million’ investment by the company. He added that the technical set-up of the site is already complete.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more